Jin Lin Hou

TL;DR: New HBV management guidelines include general management, indications for fibrosis assessment, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy.

TL;DR: Consistent with data from other phase 3 studies, single-tablet sofosbuvir-velpatasvir for 12 weeks is an efficacious and safe treatment for Asian patients with chronic HCV infection, but might have lower efficacy in those infected with HCV genotype 3b and with cirrhosis.

TL;DR: In a randomized controlled trial of patients with chronic HBV infection, entecavir therapy is associated with a low rate of adverse events over 10 years of follow up and participants in a China cohort who maintained a virologic response had a reduced risk of HBV-related outcome events including hepatocellular carcinoma.

TL;DR: In HBeAg-positive patients, lamivudine roadmap was most cost-effective; in Asia, telbivudines roadmap had comparable cost-effectiveness to lamivUDine roadmap because of the relatively low price of telb Vivudine in Asia.

TL;DR: To update HBV management guidelines, relevant new data were reviewed and assessed by experts from the region, and the significance of the reported findings was discussed and debated.